Zusammenfassung
Die Psoriasis vulgaris ist eine chronisch-entzündliche
Hauterkrankung mit einer Inzidenz von 2 – 3 % in
den industrialisierten Ländern. 20 – 30 % der
Psoriasis-Patienten erkranken im Laufe des Lebens auch an einer
Psoriasis-Arthritis. Auch chronisch-entzündliche Darmerkrankungen,
Depression, Alkohol- und Nikotinabusus sind gehäuft mit
Psoriasis assoziiert. Besonderes Augenmerk sollte auf Erkrankungen
des kardiovaskulären und metabolischen Formenkreises gelegt
werden. Die Diagnostik und Therapie der Begleiterkrankungen erfordert
eine enge interdisziplinäre Zusammenarbeit zwischen Dermatologen,
Rheumatologen, Allgemeinmedizinern, Internisten und bisweilen Ophthalmologen.
Viele Patienten nehmen unabhängig von der Psoriasis Medikamente
ein, die mit der Psoriasis-Therapie interferieren können.
Eine effektive Behandlung der Psoriasis und Psoriasis-Arthritis kann
möglicherweise das Risiko für die Begleiterkrankungen
und Mortalität senken.
Abstract
Psoriasis is a chronic inflammatory skin disease affecting 2 – 3 % of
the population in industrialized countries. 20 – 30 % of
the patients additionally suffer from psoriatic arthritis. Besides, chronic
inflammatory bowel disease, depression, alcohol abuse and smoking
are associated with psoriasis. In recent years a number of epidemiological
studies showed a substantial association of psoriasis with the metabolic
syndrome. Duration and severity of psoriasis directly contribute to
an increased cardiovascular risk and a higher mortality rate. Hence,
physicians are challenged to seek for effective treatment modalities
which not only improve the psoriasis but also take into account
the relevant comorbidities. In this review the current knowledge
of comorbidities in psoriasis patients is addressed and the impact
of systemic treatment options is discussed.
Schlüsselwörter
Psoriasis vulgaris - Psoriasis-Arthritis - Komorbiditäten - Metabolisches Syndrom
- Mortalität
Keywords
Psoriasis vulgaris - psoriatic arthritis - comorbidities - metabolic syndrome - mortality
Literatur
- 1
Azfar R S, Gelfand J M.
Psoriasis
and metabolic disease: epidemiology and pathophysiology.
Curr
Opin Rheumatol.
2008;
20
(4)
416-422
- 2
Boehncke S, Thaci D, Beschmann H, Ludwig R J, Ackermann H, Badenhoop K, Boehncke W H.
Psoriasis patients show signs of insulin
resistance.
Br J Dermatol.
2007;
157
(6)
1249-1251
- 3
Boehncke W H, Boehncke S, Schon M P.
Managing comorbid disease in patients with psoriasis.
Br
Med J.
2010;
340
b5666
- 4
Boehncke W H, Buerger C, Boehncke S.
[Co-morbidities in psoriasis vulgaris].
Hautarzt.
2009;
60
(2)
116-121
- 5
Cargill M, Schrodi S J, Chang M, Garcia V E, Brandon R, Callis K P. et al .
A
large-scale genetic association study confirms IL12B and leads to
the identification of IL23R as psoriasis-risk genes.
Am
J Hum Genet.
2007;
80
(2)
273-290
- 6
Duerr R H, Taylor K D, Brant S R, Rioux J D, Silverberg M S, Daly M J. et al .
A genome-wide association study identifies
IL23R as an inflammatory bowel disease gene.
Science.
2006;
314
(5804)
1461-1463
- 7
Finlay A Y.
Current severe psoriasis and the rule of tens.
Br
J Dermatol.
2005;
152
(5)
861-867
- 8
Finlay A Y, Khan G K.
Dermatology Life
Quality Index (DLQI)--a simple practical measure for routine clinical
use.
Clin Exp Dermatol.
1994;
19
(3)
210-216
- 9
Gelfand J M, Gladman D D, Mease P J, Smith N, Margolis D J, Nijsten T. et
al .
Epidemiology of psoriatic arthritis in the population
of the United States.
J Am Acad Dermatol.
2005;
53
(4)
573
- 10
Gelfand J M, Neimann A L, Shin D B, Wang X, Margolis D J, Troxel A B.
Risk of myocardial infarction in patients with psoriasis.
JAMA.
2006;
296
(14)
1735-1741
- 11
Gelfand J M, Troxel A B, Lewis J D, Kurd S K, Shin D B, Wang X. et
al .
The risk of mortality in patients with psoriasis:
results from a population-based study.
Arch Dermatol.
2007;
143
(12)
1493-1499
- 12
Gerdes S, Mrowietz U.
Impact of comorbidities
on the management of psoriasis.
Curr Probl Dermatol.
2009;
38
21-36
- 13
Gerdes S, Zahl V A, Knopf H, Weichenthal M, Mrowietz U.
Comedication related to comorbidities: a study in 1203 hospitalized
patients with severe psoriasis.
Br J Dermatol.
2008;
159
(5)
1116-1123
- 14
Gisondi P, Cotena C, Tessari G, Girolomoni G.
Anti-tumour necrosis
factor-alpha therapy increases body weight in patients with chronic
plaque psoriasis: a retrospective cohort study.
J Eur
Acad Dermatol Venereol.
2008;
22
(3)
341-344
- 15
Gottlieb A B, Dann F.
Comorbidities in patients
with psoriasis.
Am J Med.
2009;
122
(12)
1150-1159
- 16
Guenther L, Gulliver W.
Psoriasis comorbidities.
J Cutan Med Surg.
2009;
13 Suppl
2
S77-S87
- 17
Johnston A, Arnadottir S, Gudjonsson J E, Aphale A, Sigmarsdottir A A, Gunnarsson S I.
et al .
Obesity in psoriasis: leptin and resistin
as mediators of cutaneous inflammation.
Br J Dermatol.
2008;
159
(2)
342-350
- 18
Kaplan M J.
Cardiometabolic risk in psoriasis: differential effects of biologic
agents.
Vasc Health Risk Manag.
2008;
4
(6)
1229-1235
- 19
Kerekes G, Soltesz P, Der H, Veres K, Szabo Z, Vegvari A. et al .
Effects of biologics on
vascular function and atherosclerosis associated with rheumatoid arthritis.
Ann N Y Acad Sci.
2009;
1173
814-821
- 20
Krause R.
Ultraviolet B and blood pressure.
Lancet.
1998;
352
709-710
- 21
Ludwig R J, Boehncke W H.
Psoriasis
and risk of myocardial infarction.
JAMA.
2007;
297
(4)
362-363
- 22
Ludwig R J, Herzog C, Rostock A, Ochsendorf F R, Zollner T M, Thaci D. et
al .
Psoriasis: a possible risk factor for development
of coronary artery calcification.
Br J Dermatol.
2007;
156
(2)
271-276
- 23
Nast A, Kopp I B, Augustin M, Banditt K B, Boehncke W H, Follmann M. et al .
Evidence-based (S3) guidelines for the treatment of psoriasis
vulgaris.
J Dtsch Dermatol Ges.
2007;
5 Suppl 3
1-119
- 24
Paiva E S, Macaluso D C, Edwards A, Rosenbaum J T.
Characterisation
of uveitis in patients with psoriatic arthritis.
Ann Rheum
Dis.
2000;
59
(1)
67-70
- 25
Prodanovich S, Ma F, Taylor J R, Pezon C, Fasihi T, Kirsner R S.
Methotrexate reduces
incidence of vascular diseases in veterans with psoriasis or rheumatoid
arthritis.
J Am Acad Dermatol.
2005;
52
(2)
262-267
- 26
Qureshi A A, Dominguez P, Duffin K C, Gladman D D, Helliwell P, Mease P J, Husni M E.
Psoriatic arthritis screening tools.
J
Rheumatol.
2008;
35
(7)
1423-1425
- 27
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H.
Classification criteria
for psoriatic arthritis: development of new criteria from a large
international study.
Arthritis Rheum.
2006;
54
(8)
2665-2673
- 28
Weinberg J M.
More than skin deep.
Cutis.
2008;
82
(3)
175
Dr. Peter Weisenseel
Janssen-Cilag GmbH
Johnson & Johnson
Platz 1
41470 Neuss
Email: pweisens@its.jnj.com
